NEWS HIGHLIGHTS
Published Studies Related to Ocuflox (Ofloxacin Ophthalmic)
Aqueous and vitreous penetration of linezolid and levofloxacin after oral administration. [2010.12]
PURPOSE: To evaluate the time course of drug concentrations achieved in aqueous (AQ), vitreous (V), and serum (S) compartments after oral administration of linezolid and levofloxacin. DESIGN: Randomized, clinical trial... CONCLUSIONS: Single concomitant doses of linezolid and levofloxacin achieved AQ and V concentrations above the minimum inhibitory concentration for 90% of common ocular gram-positive and gram-negative pathogens up to 12 h after administration. The combination of linezolid and levofloxacin represents a viable option for the prophylaxis and management of endophthalmitis.
Short-term comparative study of the effects of preserved and unpreserved topical levofloxacin on the human ocular surface. [2010.12]
PURPOSE: To compare the short-term effects of preserved and unpreserved topical levofloxacin on the ocular surface of preoperative patients with age-related cataracts... CONCLUSION: Regarding the short-term effects on the ocular surface of patients with age-related cataracts, no clinically and statistically significant differences were observed between topical levofloxacin preserved with BOB and its unpreserved counterpart.
Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared with ofloxacin ophthalmic solution 0.3% after topical administration in healthy adult volunteers. [2010.03]
PURPOSE: This study evaluated the tear concentration and safety of levofloxacin ophthalmic solution 1.5%... CONCLUSION: A single dose of levofloxacin 1.5% produced tear fluid concentrations that were well above the minimum inhibitory concentration90 for typical ocular pathogens and was safe and well tolerated.
[Human aqueous humor levels of levofloxacin 0.5%, gatifloxacin 0.3% and levofloxacin 0.3% ophthalmic solution after topical dosing.] [2009.11]
OBJECTIVE: To compare the aqueous humor concentration of levofloxacin 0.5%, gatifloxacin 0.3% and levofloxacin 0.3% ophthalmic solution after topical dosing in human eyes... CONCLUSION: Topically applied levofloxacin 0.5% had the higher aqueous humor drug level than gatifloxacin 0.3% and levofloxacin 0.3%.
A prospective study determining the efficacy of topical 0.5% levofloxacin on bacterial flora of patients with chronic blepharoconjunctivitis. [2009.07]
BACKGROUND: To determine the efficacy of conjunctival bacterial eradication following a 1-day, 3-day and 7-day application of topical 0.5% levofloxacin, with and without eyelid scrub, in patients with chronic blepharoconjunctivitis (CBC)... CONCLUSIONS: CBC eyes have a significantly higher number of positive cultures than eyes without CBC. The application of topical 0.5% levofloxacin for at least 3 days provided a significant reduction in the number of positive cultures as well as the number of bacteria harbored on the conjunctival surface.
Clinical Trials Related to Ocuflox (Ofloxacin Ophthalmic)
Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia [Completed]
A trial in which patients over 18 years of age who are hospitalized with community acquired
pneumonia and are otherwise eligible for entry into the study are randomly selected to
receive one of two treatment regimens. After written informed consent is obtained, patients
will receive one of the following two treatment regimens: 1) intravenous administration of
azithromycin and ceftriaxone followed by azithromycin tablets, or 2) intravenous
administration of levofloxacin followed by levofloxacin tablets. At least four study visits
are normally conducted up to approximately one month after starting therapy. The objective
of this study is to compare the safety and efficacy of the two treatment regimens.
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation [Recruiting]
This randomized phase III trial studies how well levofloxacin works in preventing infection
in young patients with acute leukemia receiving chemotherapy or undergoing stem cell
transplant. Giving antibiotics may be effective in preventing or controlling early infection
in patients receiving chemotherapy or undergoing stem cell transplant for acute leukemia. It
is not yet known whether levofloxacin is effective in preventing infection.
Efficacy of Seven-day Combined Rabeprazole Plus Levofloxacin Plus Augmentin for Eradication of Helicobacter Pylori [Terminated]
This prospective controlled randomized open-label clinical trial is designed to determine
the eradication rate of 7-day levofloxacin, amoxicillin/clavulanate and rabeprazole regimen
compared with 7-day standard triple therapy for adults infected with Helicobacter pylori in
Eastern Taiwan.
Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment [Completed]
To examine and compare the efficacy of 2 week Levofloxacin-containing therapies with and
without Bismuth for H. pylori treatment.
"Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients". [Terminated]
A multicenter, prospective, non-inferiority, randomized and open clinical trial comparing
levofloxacin with isoniazid in the treatment of latent tuberculosis infection in patients
eligible for liver transplantation.
Patients over 18 years of age on the waiting list for liver transplantation.
Sample size: n=870 patients.
HYPOTHESIS
Levofloxacin treatment of latent tuberculosis infection, begun while on the waiting list for
liver transplantation, is safer and not less effective than isoniazid treatment begun after
transplantation when liver function is stable.
|
